Giredestrant

SKU: orb1309629

Description

Giredestrant

Research Area

Metabolism Research

Key Properties

• CAS Number: 1953133-47-5
• MW: 522.55
• Purity: 99.13%
• Formula: C₂₇H₃₁F₅N₄O
• SMILES: C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(F)(F)CO)c1c(F)cc(NC2CN(CCCF)C2)cc1F
• Target: Estrogen Receptor/ERR,Estrogen/progestogen Receptor
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (7.65 mM);DMSO:100 mg/mL (191.37 mM)

Bioactivity

• In Vitro:
  The highly potent in vivo efficacy of Giredestrant likely arises due to the particular combination of high binding potency, full suppression of ER signaling, and an improved DMPK profile.Giredestrant (GDC-9545) is a novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, non-steroidal, ligand, orally, Giredestrant, ERR, ER, Estrogen Receptor/ERR, Estrogen Receptor, EstrogenReceptor, Inhibitor, GDC 9545, GDC9545, GDC-9545, anti-tumor, change, conformational, progestogenReceptor, progestogen Receptor

Compound Identifiers

PubChem CID

121410806